Why BioNTech Stock Bumped Higher Today

A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (NASDAQ: BNTX) shares higher as the stock trading week began on Monday. The Germany-based biotech's equity rose by almost 3% in value during the session, comparing well to the 0.4% improvement of the S&P 500 index. Friday afternoon, a vaccine advisory panel of the Centers for Disease Control and Prevention (CDC) narrowly voted against recommending a doctor's prescription to obtain shots of Covid vaccines in this country. BioNTech came to prominence during the Covid era as the co-developer (with Pfizer) of the go-to jab Comirnaty. To a degree, its reputation still rests on the product. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool